Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
NCT03510442 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000
Last updated 2026-05-22
Summary
Background:
Inflammatory conditions can cause symptoms like fevers, arthritis, and rash. Systemic juvenile idiopathic arthritis (sJIA) is one of these conditions. So is adult-onset Still s disease (AOSD). Their causes are unknown. Researchers want to learn more about these conditions. This includes genetic changes and environmental factors.
Objective:
To study sJIA and AOSD in children and adults over time.
Eligibility:
People with known or suspected sJIA, AOSD, or similar inflammatory condition
Design:
Participants will be screened with a phone call.
Participants will have 1 visit. It may be outpatient or they may be admitted to the clinic. The visit may last up to 5 days. Participants will have:
* Medical history
* Physical exam
* Musculoskeletal exam
* Questions about overall health and quality of life, disease activity, functional status, and cognitive ability.
Participants may also have:
* Pictures taken of their skin, joints, or spine
* Blood, urine, and stool tests
* Scans or X-rays of joints with arthritis
* Chest X-ray
* Heart tests
* Skin biopsy. The skin will be numbed. The top layers of a small area will be scraped off.
Participants who have a joint aspiration may provide a fluid sample. The joint will be prepared, then fluid is removed by needle. A corticosteroid may be injected.
Participants who have a bone marrow biopsy may provide sample cells.
Participants may be seen by NIH specialists.
Members of the participant s family and healthy volunteers may give blood or saliva samples for genetic testing.
Participants may repeat some study tests every 6 months.
Conditions
- Still's Disease, Adult-Onset
- Systemic Inflammation
- Arthritis
- Autoinflammatory Syndrome
Sponsors & Collaborators
-
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
lead NIH
Principal Investigators
-
Michael J Ombrello, M.D. · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Eligibility
- Min Age
- 1 Day
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-05-21
- Primary Completion
- 2050-01-01
- Completion
- 2050-01-01
Countries
- United States
Study Locations
More Related Trials
-
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases
NCT04397107 ·Status: COMPLETED ·Phase: NA
-
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
NCT00144625 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults
NCT00534495 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
NCT01904292 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis
NCT06007456 ·Status: RECRUITING
-
Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis
NCT00868751 ·Status: TERMINATED ·Phase: NA
-
Research Study on the Immunosuppressive Effects of a Cell Therapy Product on PBMC Isolated From Blood of Patients With Inflammatory Rheumatic Diseases
NCT03454932 ·Status: TERMINATED
-
A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
NCT02277444 ·Status: COMPLETED ·Phase: PHASE3
-
Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes
NCT02469753 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
NCT02776735 ·Status: COMPLETED ·Phase: PHASE2
-
Articular Damage in Patients With Juvenile Idiopathic Arthritis After Transition to Adult Care
NCT06895278 ·Status: NOT_YET_RECRUITING
-
Analysis of Peripheral Blood Lymphocytes in Patients With Juvenile Idiopathic Arthritis With Respect to Disease Subtypes and Therapy
NCT06413563 ·Status: NOT_YET_RECRUITING
-
Pediatric Arthritis Study of Certolizumab Pegol
NCT01550003 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis: a Real-life Experience
NCT05182203 ·Status: COMPLETED
-
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
NCT01500551 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT03301883 ·Status: COMPLETED ·Phase: PHASE4
-
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
NCT03000439 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients
NCT01559103 ·Status: TERMINATED ·Phase: PHASE1
-
Start Time Optimization of Biologics in Polyarticular JIA
NCT02593006 ·Status: COMPLETED
-
The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis
NCT05290363 ·Status: RECRUITING ·Phase: NA
-
Biomarkers in Saliva in Children With Juvenil Idiopathic Arthritis
NCT02223195 ·Status: COMPLETED
-
Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)
NCT00779935 ·Status: COMPLETED ·Phase: PHASE4
-
Juvenile Idiopathic Arthritis (JIA) Registry
NCT00783510 ·Status: COMPLETED
-
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
NCT02882087 ·Status: TERMINATED ·Phase: PHASE2